Amae Health, a San Francisco-based startup specializing in the treatment of severe mental illness, has announced the successful raising of $25 million in Series B funding. This investment, which brings the company’s total funding to over $50 million, aims to enhance the quality of care for patients grappling with conditions such as schizophrenia, bipolar disorder, major depressive disorder, and borderline personality disorder.

Amae Health’s approach integrates outpatient care with a holistic support system, partnering with esteemed health systems including NewYork-Presbyterian, Cedars-Sinai, and Stanford Health Care. Patients benefit from a multidisciplinary team that encompasses psychiatrists, therapists, primary care physicians, dietitians, health coaches, peer mentors, and clinical care coordinators. This collaborative model is designed to address both the medical and social dimensions of mental health, an area often overlooked in traditional healthcare setups.

Stas Sokolin, CEO of Amae Health, emphasized the significance of this initiative, stating, “People living with severe mental illness are among the most underserved and stigmatized in our healthcare system. They are often excluded from research and lack access to coordinated, high-quality care that addresses both medical and social needs.” He noted that many health systems are overwhelmed by competing priorities, which impedes their ability to provide the comprehensive support required for this vulnerable population. Amae Health was founded with the mission to change this narrative.

The Series B round saw active participation from a range of investors, including Altos Ventures, Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital, and 8VC. The funding will facilitate the opening of additional clinics across the country, currently located in California, North Carolina, and New York, while also expanding academic medical center partnerships and advancing research focused on schizophrenia, bipolar disorder, and treatment-resistant depression.

Furthermore, the financing is set to propel the development of Amae Health’s AI-driven platform, which offers a patient data dashboard that consolidates health information, monitors changes, and identifies symptom patterns. This technological advancement aims to enhance the personalization of care provided to patients.

Amae Health’s innovative model is already showing promising results. The company reports a reduction in 30-day hospital readmissions to approximately 4%, considerably lower than the national average of 23%. Additionally, through its measurement-based care approach, Amae has achieved notable score improvements of 76% for mania, 61% for psychosis, and 49% for suicidality.

Dr. Itai Danovitch, chair of the Department of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center, commended Amae Health’s commitment to excellence. He stated, “Amae is advancing a model of care that prioritizes clinical excellence and compassionate, patient-centered services.